塞内加尔HIV-2感染抗逆转录病毒治疗的长期项目经验与结局
该前瞻性纵向观察队列研究纳入291名接受塞内加尔国家艾滋病规划抗逆转录病毒治疗的HIV-2成人感染者,随访13年共926.0人年。结果显示治疗中76.7%的血浆病毒载量被抑制,但40.2%失访、7.2%死亡,且56%的病毒学失败者存在多类耐药,提示HIV-2治疗结局虽有改善但仍不理想。
要点
- 队列中76.7%的治疗者病毒载量被抑制,但40.2%失访、7.2%死亡。
- UNAIDS 90-90-90策略发布后,88.1%的病毒载量被抑制。
核心结论
- 塞内加尔国家艾滋病规划中HIV-2感染者启动治疗更早且现代方案改善了治疗结局,但整体治疗仍不理想,改善关怀面临重大挑战。
研究设计与样本
- 前瞻性纵向观察队列研究,在塞内加尔2个中心纳入291名启动或接受抗逆转录病毒治疗的HIV-2成人,随访13年共926.0人年,中位随访2.2年/人。
主要发现
- 报告死亡21例(7.2%),失访117人(40.2%),其中43人(14.7%)仅初次就诊后未再随访。
- 入组时CD4计数和HIV-2病毒抑制(<50 copies/mL)随日历时间增加。
- 研究期间接受治疗者76.7%的血浆病毒载量被抑制,治疗前2年中位CD4增加84 cells/μL。
- UNAIDS 90-90-90策略发布后,88.1%的病毒载量被抑制。
临床怎么用
- 应关注HIV-2治疗者的病毒载量监测和耐药检测,尤其对病毒学失败者警惕多类耐药。
- 需加强随访管理以减少高失访率,并持续优化治疗方案以改善病毒抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmatic treatment outcome data for people living with human immunodeficiency virus type 2 (HIV-2) in West Africa, where the virus is most prevalent, are scarce. METHODS: Adults with HIV-2 initiating or receiving antiretroviral therapy (ART) through the Senegalese national AIDS program were invited to participate in this prospective, longitudinal observational cohort study. We analyzed HIV-2 viral loads, CD4 cell counts, antiretroviral drug resistance, loss to follow-up, and mortality. We also examined changes in treatment guidelines over time and assessed progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets for HIV-2. RESULTS: We enrolled 291 participants at 2 sites for 926.0 person-years of follow-up over 13 years. Median follow-up time was 2.2 years per participant. There were 21 deaths reported (7.2%), and 117 individuals (40.2%) were lost to follow-up, including 43 (14.7%) who had an initial visit but never returned for follow-up. CD4 counts and HIV-2 viral suppression (< 50 copies/mL) at enrollment increased over calendar time. Over the study period, 76.7% of plasma viral loads for participants receiving ART were suppressed, and median CD4 gain was 84 cells/μL in participants' first 2 years on study. Since the UNAIDS 90-90-90 strategy was published, 88.1% of viral loads were suppressed. Fifteen percent of patients experienced virologic failure with no known resistance mutations, while 56% had evidence of multiclass drug resistance. CONCLUSIONS: Participants in the Senegalese national AIDS program are initiating ART earlier in the course of disease, and more modern therapeutic regimens have improved outcomes among those receiving therapy. Despite these achievements, HIV-2 treatment remains suboptimal, and significant challenges to improving care remain.
引用
- Raugi DN, Ba S, Cisse O, et al. Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa. Clin Infect Dis. 2021. PMID: 33527119. doi:10.1093/cid/ciaa277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。